Cortisol Evaluation in Abuse Survivors
Information source: University of Bristol
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Domestic Violence; Depression; Anxiety; Panic Disorder; Posttraumatic Stress Disorders
Phase: N/A
Status: Active, not recruiting
Sponsored by: University of Bristol Official(s) and/or principal investigator(s): Gene Feder, Professor, Principal Investigator, Affiliation: University of Bristol, Centre for Academic Primary Care Stafford Lightman, Professor, Study Chair, Affiliation: University of Bristol, School of Clinical Sciences Natalia Lokhmatkina, PhD, Study Director, Affiliation: University of Bristol, School of Clinical Sciences
Summary
This study looks at the biological effect of domestic violence and abuse (DVA) on women's
mental health. The mechanisms through which DVA causes mental disorders are very poorly
understood. Similar to other demands, DVA activates the biological stress system, of which
the chief component is the hypothalamic-pituitary-adrenal (HPA) axis, which produces
chemical cortisol. Cortisol levels increase in response to short-term demand and help
organisms deal with it by changing the processes of getting energy from food and also mental
function. However constant activation of the HPA axis can cause damage and accelerate
disease.
This study tests the hypothesis that compared to non-abused women all abuse victims have
altered diurnal rhythm in cortisol secretion and that the pattern of this alteration is
predicted by abuse characteristics, such as its type, severity, duration, and cessation. To
examine the hypothesis the following research questions will be addressed: 1) whether
cortisol levels are related to mental health state; 2) whether cortisol levels are related
to type, severity, duration and cessation of DVA; 3) whether there is any difference in
cortisol concentrations between those women exposed to both childhood abuse and DVA and
those who have experienced only the latter; 4) whether cortisol levels vary between women,
living in refuge and those not living in refuge?
To answer these research questions 214 women will be recruited in a domestic violence
agency. Baseline and 3-monthly follow-up measures will be taken over 6 months after
recruitment. Women will be asked to fill in a questionnaire to evaluate their demographics,
health, experience of childhood abuse and DVA. Women's weight and height will be taken. In
addition participants will be asked to take three saliva samples: 1st in the evening in bed,
2nd - next morning immediately upon awakening, and the 3rd - in thirty minutes after
awakening. Saliva will be collected by chewing (for 2 minutes) the cotton pledget provided
with plastic tube and returned by post or via collection by the researcher. Then the saliva
samples will be tested for cortisol and cortisone.
Results of the study will increase our understanding of the biological mechanisms of DVA
impact on a woman's health and tell researchers and practitioners about the possibility of
using cortisol as an indicator to diagnose abuse-related health problems and assess
effectiveness of medical care for abuse survivors.
Clinical Details
Official title: Longitudinal Measurement of Cortisol in Association With Mental Health and Experience of Domestic Violence and Abuse
Study design: Observational Model: Case Control, Time Perspective: Prospective
Primary outcome: Diurnal cortisol variation
Secondary outcome: Cortisol awakening response (CAR)Mean salivary cortisol concentration
Detailed description:
Domestic violence and abuse (DVA) is threatening behavior, violence or abuse (psychological,
physical, sexual, financial or emotional) used by one person to control the other. Life time
prevalence of DVA is 28% for women and 18% for men, although severity and consequences of
abuse are less for men (1). Over and above damage to physical and reproductive health DVA
has long-term detrimental effects on mental health for women consulting in primary care (2,
3). A meta-analysis of studies measuring the relationship between DVA and mental disorders
reported increased risk for depression, anxiety, psychosomatic disorders, posttraumatic
stress disorder (PTSD), alcohol abuse, and suicidal behavior (4). Kernic et al (5) have
established that cessation of DVA among survivors is associated with decreased prevalence of
depression; whereas Anderson and Sounders (6) have found that some women out of the abusive
relationship may have greater psychological difficulties than those who are still in it.
However the mechanisms through which DVA causes mental disease are very poorly understood.
Similar to other stressors, DVA activates the biological stress system, of which the
principal component is the hypothalamic-pituitary-adrenal (HPA) axis, which produces
cortisol. Chronic activation of this system can result in dendritic retraction and
hippocampal loss of function (7, 8). The results of existing cross-sectional studies testing
the impact of DVA on women's HPA axis functioning are contradictory. Pico-Alfonso et al (9)
have reported an increase in cortisol levels, whilst Seedat et al (10) have established
reduction in cortisol levels in DVA subjects compared to controls. This disparity may relate
to differential development of PTSD and/or depression within DVA-exposed samples (11).
Currently, there is a hypothesis that DVA survivors may be characterized by alterations in
the HPA axis (12) and that further longitudinal studies are needed to identify specific
stress system disturbances in this group (1, 13). The aim of the study is to increase
understanding of the role of hypothalamic-pituitary-adrenal (HPA) axis activity in DVA
impact on women's mental health.
Study objectives:
- To evaluate the profiles of the awakening response of cortisol, the diurnal variation
and the mean salivary cortisol concentration in women with experience of DVA and in
non-abused controls
- To estimate whether cortisol secretion is associated with type, severity, duration and
cessation of DVA
- To investigate whether cortisol acts as mediator between DVA and mental health state
- To examine whether there is any distinction in cortisol levels between those women
exposed to both childhood abuse and DVA and those experienced only the latter
- To explore whether cortisol secretion differs between women, living in a domestic
violence refuge/safe house and those still living in the community (after adjustment
for confounding effects of abuse severity and continuing contact with abuser).
This 6-month study will consist of 3 measurements every 3 months. Each assessment will last
approximately 30-45 minutes and will include:
1. Numerous standardized self-administered psychological questionnaires
2. Weight and height measurement
3. Self-completion of 3 saliva samples using Salivette tubes:
1. evening sample - at bedtime
2. awakening sample - in the morning immediately upon wakening
3. post-awakening sample - 30 mins after awakening sample
Tubes with saliva will be returned by post or by researcher to an accredited laboratory for
cortisol assay. The analysis also simultaneously measures cortisone a breakdown product of
cortisol. This measurement is used to confirm the integrity of the sample.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- age ≥ 18 y. o.
Exclusion Criteria:
- unable to read English
- current use of steroid-based medications
- pregnancy
- presence of adrenal and/or pituitary gland disorder
- symptomatic psychotic illness.
Locations and Contacts
Next Link, Bristol BS1 4JQ, United Kingdom
Survive South Gloucestershire and Bristol, Kingswood, Bristol BS15 8XJ, United Kingdom
Additional Information
protocol paper in Open Access
Related publications: Feder G, Ramsay J, Dunne D, Rose M, Arsene C, Norman R, Kuntze S, Spencer A, Bacchus L, Hague G, Warburton A, Taket A. How far does screening women for domestic (partner) violence in different health-care settings meet criteria for a screening programme? Systematic reviews of nine UK National Screening Committee criteria. Health Technol Assess. 2009 Mar;13(16):iii-iv, xi-xiii, 1-113, 137-347. doi: 10.3310/hta13160. Review. Campbell JC. Health consequences of intimate partner violence. Lancet. 2002 Apr 13;359(9314):1331-6. Review. Coid J, Petruckevitch A, Chung WS, Richardson J, Moorey S, Feder G. Abusive experiences and psychiatric morbidity in women primary care attenders. Br J Psychiatry. 2003 Oct;183:332-9; discussion 340-1. Golding JM. Intimate partner violence as a risk factor for mental disorders: A meta-analysis. Journal of Family Violence 14(2):99-132, 1999. Kernic MA, Holt VL, Stoner JA, Wolf ME, Rivara FP. Resolution of depression among victims of intimate partner violence: is cessation of violence enough? Violence Vict. 2003 Apr;18(2):115-29. Anderson DK, Saunders DG. Leaving an abusive partner: an empirical review of predictors, the process of leaving, and psychological well-being. Trauma Violence Abuse. 2003 Apr;4(2):163-91. Review. Lightman SL. The neuroendocrinology of stress: a never ending story. J Neuroendocrinol. 2008 Jun;20(6):880-4. doi: 10.1111/j.1365-2826.2008.01711.x. Review. Mirescu C, Gould E. Stress and adult neurogenesis. Hippocampus. 2006;16(3):233-8. Review. Pico-Alfonso MA, Garcia-Linares MI, Celda-Navarro N, Herbert J, Martinez M. Changes in cortisol and dehydroepiandrosterone in women victims of physical and psychological intimate partner violence. Biol Psychiatry. 2004 Aug 15;56(4):233-40. Seedat S, Stein MB, Kennedy CM, Hauger RL. Plasma cortisol and neuropeptide Y in female victims of intimate partner violence. Psychoneuroendocrinology. 2003 Aug;28(6):796-808. McFarlane AC, Barton CA, Yehuda R, Wittert G. Cortisol response to acute trauma and risk of posttraumatic stress disorder. Psychoneuroendocrinology. 2011 Jun;36(5):720-7. doi: 10.1016/j.psyneuen.2010.10.007. Epub 2010 Nov 19. Erratum in: Psychoneuroendocrinology. 2011 Nov;36(10):1587. Heim C, Ehlert U, Hanker JP, Hellhammer DH. Abuse-related posttraumatic stress disorder and alterations of the hypothalamic-pituitary-adrenal axis in women with chronic pelvic pain. Psychosom Med. 1998 May-Jun;60(3):309-18. Dutton MA, Green BL, Kaltman SI, Roesch DM, Zeffiro TA, Krause ED. Intimate partner violence, PTSD, and adverse health outcomes. J Interpers Violence. 2006 Jul;21(7):955-68. Review. Lokhmatkina NV, Feder G, Blake S, Morris R, Powers V, Lightman S. Longitudinal measurement of cortisol in association with mental health and experience of domestic violence and abuse: study protocol. BMC Psychiatry. 2013 Jul 13;13:188. doi: 10.1186/1471-244X-13-188.
Starting date: August 2012
Last updated: April 30, 2014
|